IJMSPH

International Journal of Medical Science and Public Health

« Previous Article
Next Article »

Review Article Open Access


Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach

Kapil Kumar Garg, S N Chugh.

Abstract
Type 2 diabetes mellitus (T2DM) remains uncontrolled in a large number of patients despite advances in medical treatment. Bromocriptine mesylate is a quick release preparation of bromocriptine, which acts on hypothalamic pathways of glucose metabolism. It represents a novel therapeutic option in the management of T2DM. United States Food and Drug Administration in 2009 approved the use of bromocriptine mesylate in T2DM as an adjunct to diet and exercise. Various clinical trials have demonstrated the efficacy of bromocriptine mesylate in lowering glycosylated hemoglobin by 0.4 to 0.8% as monotherapy or add-on therapy with other antidiabetic agents. Action on central pathways affecting glucose metabolism makes it a great alternative to current modalities of treatment for T2DM.

Key words: Bromocriptine; Dopamine Agonists; Diabetes; Insulin Resistance


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Kapil Kumar Garg
Articles by S N Chugh
on Google
on Google Scholar
Article Statistics
 Viewed: 139
Downloaded: 43
Cited: 0

How to Cite this Article
Pubmed Style

Garg KK, Chugh SN. Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach. Int J Med Sci Public Health. 2017; 6(6): 987-991. doi:10.5455/ijmsph.2017.0308007042017



Web Style

Garg KK, Chugh SN. Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach. www.scopemed.org/?mno=262793 [Access: June 23, 2017]. doi:10.5455/ijmsph.2017.0308007042017



AMA (American Medical Association) Style

Garg KK, Chugh SN. Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach. Int J Med Sci Public Health. 2017; 6(6): 987-991. doi:10.5455/ijmsph.2017.0308007042017



Vancouver/ICMJE Style

Garg KK, Chugh SN. Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach. Int J Med Sci Public Health. (2017), [cited June 23, 2017]; 6(6): 987-991. doi:10.5455/ijmsph.2017.0308007042017



Harvard Style

Garg, K. K. & Chugh, S. N. (2017) Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach. Int J Med Sci Public Health, 6 (6), 987-991. doi:10.5455/ijmsph.2017.0308007042017



Turabian Style

Garg, Kapil Kumar, and S N Chugh. 2017. Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach. International Journal of Medical Science and Public Health, 6 (6), 987-991. doi:10.5455/ijmsph.2017.0308007042017



Chicago Style

Garg, Kapil Kumar, and S N Chugh. "Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach." International Journal of Medical Science and Public Health 6 (2017), 987-991. doi:10.5455/ijmsph.2017.0308007042017



MLA (The Modern Language Association) Style

Garg, Kapil Kumar, and S N Chugh. "Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach." International Journal of Medical Science and Public Health 6.6 (2017), 987-991. Print. doi:10.5455/ijmsph.2017.0308007042017



APA (American Psychological Association) Style

Garg, K. K. & Chugh, S. N. (2017) Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach. International Journal of Medical Science and Public Health, 6 (6), 987-991. doi:10.5455/ijmsph.2017.0308007042017



latest news

Retraction notice [Dec 03, 2016]
Retraction notice [Mar 02, 2015]
Submission of article [Jul 22, 2012]


The articles in this Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.